RESUMO
OBJECTIVES: This study investigated the efficacy of a transcutaneous electrical nerve stimulation (TENS) device (Quell®) for persons with symptoms due to fibromyalgia (FM). MATERIALS AND METHODS: One hundred nineteen (N = 119) subjects were randomly assigned to use an active (N = 62) or sham (N = 57) TENS for three months. All subjects completed baseline questionnaires and were administered quantitative sensory testing (QST). Subjects completed the Patients' Global Impression of Change (PGIC, primary outcome measure) and other mailed questionnaires (secondary outcome measures) at six weeks and three months. RESULTS: The subjects averaged 50.4 ± 13.5 years of age, 93.3% were female, and 79.8% were Caucasian. Most showed benefit from using the TENS, but no differences between groups were found on the primary outcome measure after three months (active 3.87 ± 1.85, sham 3.73 ± 1.80, 95% confidence interval [CI] [-0.60, 0.88], p = 0.707). Those with more hypersensitivity showed most improvement on the PGIC at six weeks (0.22, 95% CI [0.01, 0.43], p = 0.042) and three months (0.20, 95% CI [0.00, 0.41], p = 0.049) and among those with higher sensitivity based on QST, the active TENS group showed the most benefit with TENS compared with the sham treatment (1.20, 95% CI [0.22, 2.18], p = 0.017). No TENS-related serious adverse events were reported. Subjects in the sham group correctly identified their treatment 87.5% of the time, while, surprisingly, subjects in the active group correctly identified their treatment only 17.4% of the time. CONCLUSION: This study found no differences between those who were exposed to maximal-frequency active stimulation or minimal-frequency sham stimulation from a wearable TENS in reducing FM-related symptoms. However, those with greater hypersensitivity showed most benefit from TENS. Additional studies to help determine the role individual differences play in the use of TENS in managing FM-related symptoms are needed.
Assuntos
Fibromialgia , Estimulação Elétrica Nervosa Transcutânea , Dispositivos Eletrônicos Vestíveis , Humanos , Feminino , Idoso de 80 Anos ou mais , Masculino , Fibromialgia/diagnóstico , Fibromialgia/terapia , Dor , Manejo da DorRESUMO
Crataegus oxyacantha has been mainly used in traditional medicine for the treatment of cardiovascular diseases. However, its safety profile has not been fully established, since only the genotoxic effects of C. oxyacantha fruit have been described. Therefore, the objective of this work was evaluating the cytotoxicity and genotoxicity of the aqueous and hydroalcoholic leaf and bark extracts of C. oxyacantha by means of the micronucleus test in a murine model. Doses of 2000, 1000, and 500 mg/kg of both extracts were administered orally for 5 days in mice of the Balb-C strain. Peripheral blood smears were performed at 0, 24, 48, 72, and 96 h after each administration. The number of polychromatic erythrocytes (PCEs), micronucleated polychromatic erythrocytes (MNPCEs), and micronucleated erythrocytes (MNEs) was determined at the different sampling times. Our results showed that the leaf and bark of C. oxyacantha increase the number of MNEs at the 2000 mg/kg dose, and only the aqueous leaf extract decreases the number of PCEs at the same dose. Therefore, the aqueous and hydroalcoholic leaf and bark extracts of C. oxyacantha showed genotoxic effects, and only the aqueous leaf extract exhibited cytotoxic effects.
RESUMO
BACKGROUND: Control of chronic pain and mainly the partial or complete loss of response to analgesics is a major unmet need. Multiple mechanisms underline the development of tolerance to analgesics in general and specifically to opioids. The autonomic nervous system (ANS) plays a role in the development of analgesic tolerance and chronobiology. OBJECTIVES: To review the mechanisms associated with the development of nonresponsiveness to analgesics. STUDY DESIGN: Literature review. SETTING: The review is followed by a description of a new method for overcoming resistance and improving the response to analgesics. METHODS: Conducted a detailed review of the relevant studies describing the mechanisms that underlie tolerance to pain medications, and the potential roles of the ANS and chronobiology in the development of drug resistance. RESULTS: The autonomic balance is reflected by heart rate variability, an example of a fundamental variability that characterizes biological systems. Chronotherapy, which is based on the circadian rhythm, can improve the efficacy and reduce the toxicity of chronic medications. In this article, we present the establishment of an individualized variability- and chronobiology-based therapy for overcoming the compensatory mechanisms associated with a loss of response to analgesics. We describe the premise of implementing personalized signatures associated with the ANS, and chronobiology, as well as with the pathophysiology of pain for establishing an adaptive model that could improve the efficacy of opioids, in a highly dynamic system. LIMITATIONS: The studies presented were selected based on their relevance to the subject. CONCLUSIONS: The described variability-based system may ensure prolonged effects of analgesics while reducing the toxicity associated with increasing dosages.
Assuntos
Analgésicos , Cronoterapia , Analgésicos/uso terapêutico , Analgésicos Opioides/uso terapêutico , Sistema Nervoso Autônomo , Humanos , Dor/tratamento farmacológicoRESUMO
OBJECTIVE: This controlled trial examined the benefit of a high-frequency transcutaneous electrical nerve stimulation (hfTENS) device (the Quell, NeuroMetrix, Inc., Waltham, MA, U.S.A.) for patients with chronic low back pain (CLBP). METHODS: Thirty-five (n = 35) participants were randomly assigned to use the device each day for 3 months (experimental group) and were compared with 33 subjects without the device (treatment-as-usual control group). All patients were instructed to complete baseline questionnaires and were assessed on thresholds of pressure pain and mechanical temporal summation as part of standardized quantitative sensory testing (QST). The subjects also uploaded smartphone applications (apps) for tracking use of the hfTENS and for daily pain assessment. Each participant completed weekly phone interviews, was prompted to complete daily pain app assessments, and was asked to repeat the baseline questionnaires again after 6 weeks and 3 months. RESULTS: Sixty percent of the subjects were female, 77.9% were Caucasian, and the average age was 46.2 years. Significant reductions in pain intensity (P < 0.01) and activity interference (P < 0.025) and significant improvements in pain catastrophizing (P < 0.025) were noted in the experimental group compared with the control group. No group differences were found on depression, anxiety, or pain-related disability. Older subjects with a longer duration of pain tended to use the hfTENS more often. Subjects who showed greater sensitivity based on QST results revealed increased use of the hfTENS (P < 0.025) and tended to believe that the hfTENS was more helpful in reducing their back pain, but these findings did not reach significance (P = 0.09). CONCLUSION: These results suggest that hfTENS can have a moderate effect in reducing pain and improving quality of life in low back pain patients. Further trials designed to determine the mechanism of action of the hfTENS are needed.
Assuntos
Dor Lombar/terapia , Manejo da Dor/métodos , Estimulação Elétrica Nervosa Transcutânea/métodos , Adulto , Feminino , Humanos , Masculino , Pessoa de Meia-IdadeRESUMO
UNLABELLED: Eliciting broadly reactive functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine development that is complicated by variations in envelope (Env) subtype and structure. The majority of new global HIV-1 infections are subtype C, and novel antigenic properties have been described for subtype C Env proteins. Thus, an HIV-1 subtype C Env protein (CO6980v0c22) from an infected person in the acute phase (Fiebig stage I/II) was developed as a research reagent and candidate immunogen. The gp145 envelope is a novel immunogen with a fully intact membrane-proximal external region (MPER), extended by a polylysine tail. Soluble gp145 was enriched for trimers that yielded the expected "fan blade" motifs when visualized by cryoelectron microscopy. CO6980v0c22 gp145 reacts with the 4E10, PG9, PG16, and VRC01 HIV-1 neutralizing monoclonal antibodies (MAbs), as well as the V1/V2-specific PGT121, 697, 2158, and 2297 MAbs. Different gp145 oligomers were tested for immunogenicity in rabbits, and purified dimers, trimers, and larger multimers elicited similar levels of cross-subtype binding and neutralizing antibodies to tier 1 and some tier 2 viruses. Immunized rabbit sera did not neutralize the highly resistant CO6980v0c22 pseudovirus but did inhibit the homologous infectious molecular clone in a peripheral blood mononuclear cell (PBMC) assay. This Env is currently in good manufacturing practice (GMP) production to be made available for use as a clinical research tool and further evaluation as a candidate vaccine. IMPORTANCE: At present, the product pipeline for HIV vaccines is insufficient and is limited by inadequate capacity to produce large quantities of vaccine to standards required for human clinical trials. Such products are required to evaluate critical questions of vaccine formulation, route, dosing, and schedule, as well as to establish vaccine efficacy. The gp145 Env protein presented in this study forms physical trimers, binds to many of the well-characterized broad neutralizing MAbs that target conserved Env epitopes, and induce cross-subtype neutralizing antibodies as measured in both cell line and primary cell assays. This subtype C Env gp145 protein is currently undergoing good manufacturing practice production for use as a reagent for preclinical studies and for human clinical research. This product will serve as a reagent for comparative studies and may represent a next-generation candidate HIV immunogen.
Assuntos
Vacinas contra a AIDS/imunologia , Infecções por HIV/imunologia , HIV-1/imunologia , Produtos do Gene env do Vírus da Imunodeficiência Humana/imunologia , Vacinas contra a AIDS/administração & dosagem , Vacinas contra a AIDS/genética , Animais , Avaliação Pré-Clínica de Medicamentos , Anticorpos Anti-HIV/imunologia , Infecções por HIV/prevenção & controle , Infecções por HIV/virologia , HIV-1/genética , Humanos , Leucócitos Mononucleares/imunologia , Dados de Sequência Molecular , Testes de Neutralização , Coelhos , Vacinação , Produtos do Gene env do Vírus da Imunodeficiência Humana/administração & dosagem , Produtos do Gene env do Vírus da Imunodeficiência Humana/genéticaRESUMO
La malaria o paludismo, enfermedad causada por protozoos parásitos de género Plasmodium , se considera un gran problema de salud pública mundial por sus elevadas tasas de morbimortalidad. Las manifestaciones clínicas de esta infección van desde un síndrome febril agudo hasta un cuadro de malaria complicada que afecta órganos específicos, pudiendo progresar a una falla multisistémica que comprometa la vida del paciente. En la malaria, el riñón es un órgano susceptible de daño por mecanismos fisiopatológicos directos del plasmodio como el secuestro de glóbulos rojos parasitados, la obstrucción de la microcirculación y la activación del sistema inmune; además, por efectos indirectos hematológicos, hepáticos y metabólicos. La lesión renal en malaria se ha informado en Colombia hasta en el 31% de los pacientes con malaria grave; incluye la lesión renal aguda y el síndrome nefrótico, cada uno con manifestaciones clínicas, implicaciones terapéuticas y factores pronósticos propios. La lesión renal aguda es la condición más frecuente y puede llevar a una acidosis metabólica grave, daño renal crónico e incluso, cuando hace parte de una falla multiorgánica, asociarse con mortalidad que alcanza tasas de entre 40 y 50%. Un mejor entendimiento de la fisiopatología de la lesión renal en la malaria permitirá reconocer las manifestaciones clínicas para hacer un diagnóstico temprano e iniciar un tratamiento oportuno, con los beneficios que esto conlleva para la evolución y pronóstico del paciente.
Assuntos
Humanos , Adulto , Patogenesia Homeopática , Injúria Renal Aguda , Rim , Malária , Acidose , Sistema Imunitário , Nefropatias , Síndrome NefróticaRESUMO
Intractable chronic headaches are a major challenge for both patients and healthcare professionals. Over the last two decades, implantable electrical neuromodulators, previously established to manage other forms of chronic pain, have been used increasingly for intractable primary and secondary headache disorders. We review the current approaches to the management of refractory headaches using neuromodulation. Indications, operative considerations and complications are discussed based on our experience and a review of the literature. The field of neuromodulation has been rapidly advancing, with many new targets being discovered and novel devices being developed for treating craniofacial pain. We discuss some of these targets, detailing the latest advances in the area of neuromodulation for intractable headaches.
Assuntos
Terapia por Estimulação Elétrica , Dor Facial/terapia , Transtornos da Cefaleia Primários/terapia , Transtornos da Cefaleia Secundários/terapia , Transtornos da Cefaleia/terapia , Mapeamento Encefálico , Nervos Cranianos/fisiopatologia , Dor Facial/fisiopatologia , Feminino , Transtornos da Cefaleia/fisiopatologia , Transtornos da Cefaleia Primários/fisiopatologia , Transtornos da Cefaleia Secundários/fisiopatologia , Humanos , Masculino , Seleção de Pacientes , Processamento de Sinais Assistido por Computador , Transmissão Sináptica , Resultado do TratamentoRESUMO
The Curiosity rover discovered fine-grained sedimentary rocks, which are inferred to represent an ancient lake and preserve evidence of an environment that would have been suited to support a martian biosphere founded on chemolithoautotrophy. This aqueous environment was characterized by neutral pH, low salinity, and variable redox states of both iron and sulfur species. Carbon, hydrogen, oxygen, sulfur, nitrogen, and phosphorus were measured directly as key biogenic elements; by inference, phosphorus is assumed to have been available. The environment probably had a minimum duration of hundreds to tens of thousands of years. These results highlight the biological viability of fluvial-lacustrine environments in the post-Noachian history of Mars.
Assuntos
Exobiologia , Meio Ambiente Extraterreno , Marte , Água , Baías , Carbono/análise , Sedimentos Geológicos/análise , Sedimentos Geológicos/classificação , Hidrogênio/análise , Concentração de Íons de Hidrogênio , Ferro/análise , Ferro/química , Nitrogênio/análise , Oxirredução , Oxigênio/análise , Fósforo/análise , Salinidade , Enxofre/análise , Enxofre/químicaRESUMO
PURPOSE: E6201 is a natural product-inspired novel inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-1 (MEK1) and other kinases and is currently under development as an anticancer (parenteral administration) and antipsoriasis agent (topical application). In vitro and in vivo preclinical studies were performed to characterize the pharmacokinetics of E6201. Allometric scaling was applied to predict human pharmacokinetics of E6201. METHODS: In vitro metabolism studies for CYP induction and CYP inhibition were conducted using human hepatocytes and microsomes, respectively. Metabolic stability using microsomes and protein-binding studies using pooled plasma were performed for mice, rats, dogs, and human. Pharmacokinetics of E6201 and its isomeric metabolite, ER-813010, in mice, rats, and dogs was determined following single IV administration of E6201 at three dose levels. Bioanalysis was performed using LC/MS/MS. Pharmacokinetic parameters were determined using non-compartmental analysis, and allometric scaling with a two-compartment model was used to predict E6201 pharmacokinetics in humans. RESULTS: E6201 showed high plasma protein binding (>95%), and metabolic stability half-life ranged from 36 to 89 min across species. In vitro CYP inhibition (CYP1A2, 2C9, 2C19, 2D6, 2E1, and 3A) and CYP induction (CYP1A, 3A, 2C9, and 2C19) suggested no inhibitory or induction effect on the tested human CYPs up to 10 µM of E6201. Pharmacokinetics of E6201 in mice, rats, and dogs was characterized by mean clearance ranging from 3.45 to 10.92 L/h/kg, distribution volume ranging from 0.63 to 13.09 L/kg, and elimination half-life ranging from 0.4 to 1.6 h. ER-813010 was detected in all species with metabolite to parent exposure ratio (AUC(R)) ranging from 3.1 to 33.4% and exhibited fast elimination (<3 h). The allometry predicted high clearance and large volume of distribution of E6201 in humans and was in general in good agreement with the observed first human subject pharmacokinetics. CONCLUSIONS: E6201 exhibited high clearance, high to moderate distribution, and fast elimination in preclinical species. In vitro results suggested that E6201 has low risk of drug-drug interactions due to CYP inhibition and induction in humans. In the first-in-man study, E6201 exhibited high clearance, which was well predicted by allometric scaling.
Assuntos
Inibidores das Enzimas do Citocromo P-450 , Lactonas/farmacocinética , MAP Quinase Quinase 1/antagonistas & inibidores , Animais , Cromatografia Líquida , Cães , Avaliação Pré-Clínica de Medicamentos , Meia-Vida , Humanos , Lactonas/administração & dosagem , Masculino , Camundongos , Camundongos Endogâmicos BALB C , Microssomos Hepáticos , Ligação Proteica , Ratos , Ratos Sprague-Dawley , Especificidade da Espécie , Espectrometria de Massas em Tandem , Distribuição TecidualRESUMO
CONTEXT: Inadequate dietary protein intake has been implicated in sarcopenia. OBJECTIVE AND DESIGN: The objectives of this study were to determine whether: 1) chronic essential amino acid (EAA) supplementation improves postabsorptive muscle protein fractional synthesis rate (FSR), lean body mass (LBM), and one-repetition maximum muscle strength, and androgen receptor and IGF-I muscle protein expression; and 2) the acute anabolic response to EAA ingestion is preserved after a 3-month supplementation period. Using a randomized, double-blinded, placebo-controlled design, older women (68 +/- 2 yr) were assigned to receive either placebo (n = 7), or 15 g EAA/d [supplemented treatment group (SUP)] (n = 7) for 3 months. Metabolic outcomes were assessed in association with stable isotope studies conducted at 0 and 3 months. SETTING: The study was performed at The University of Texas Medical Branch General Clinical Research Center. RESULTS: Ingestion of 7.5 g EAA acutely stimulated FSR in both groups at 0 months (P < 0.05). Basal FSR at 3 months was increased in SUP only. The magnitude of the acute response to EAA was unaltered after 3 months in SUP. LBM increased in SUP only (P < 0.05). One-repetition maximum strength remained unchanged in both groups. Basal IGF-I protein expression increased in SUP after 3 months (P = 0.05), with no changes in androgen receptor or total and phosphorylated Akt, mammalian target of rapamycin, S6 kinase, and 4E-binding protein. CONCLUSIONS: EAA improved LBM and basal muscle protein synthesis in older individuals. The acute anabolic response to EAA supplementation is maintained over time and can improve LBM, possibly offsetting the debilitating effects of sarcopenia.
Assuntos
Aminoácidos Essenciais/uso terapêutico , Composição Corporal/efeitos dos fármacos , Suplementos Nutricionais , Fator de Crescimento Insulin-Like I/biossíntese , Proteínas Musculares/biossíntese , Absorciometria de Fóton , Idoso , Anabolizantes/farmacologia , Western Blotting , Feminino , Humanos , Insulina/sangue , Cinética , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Fenilalanina/farmacologia , Receptores Androgênicos/biossínteseAssuntos
Tomada de Decisões Gerenciais , Reforma dos Serviços de Saúde/organização & administração , Administração Hospitalar/normas , Recursos Humanos de Enfermagem Hospitalar/organização & administração , Canadá , Análise Custo-Benefício , Administração Hospitalar/economia , Humanos , Programas Nacionais de Saúde/organização & administração , Papel do Profissional de Enfermagem , Inovação Organizacional , Avaliação de Resultados em Cuidados de SaúdeRESUMO
OBJECTIVE: To explore resources used by women completing treatment for breast cancer, how they learned about them, and the psychological factors that predicted their use. DESIGN: A questionnaire on resource use was administered as part of a randomized clinical trial which assessed subjects' psychosocial characteristics and tested the outcomes of a psychosocial intervention. SETTING: Women completing treatment for breast cancer were recruited from the oncology departments of three university-teaching hospitals in Montreal. A questionnaire gathered data on the resources used by the subjects, how they learned about them, and the role of the health care team in their decision-making. Emotional distress, dimensions of coping effort, a sense of control and optimism were also measured. RESULTS: Five categories of resources were explored; professional services, informal support networks, informational resources, support organizations and complementary therapies. Most women found out about the last two resources by themselves. Women who used cancer support organizations or complementary therapies scored high on the use of problem-solving coping and low on the use of escape/avoidance coping. In addition they were moderately optimistic, had a slightly lower sense of personal control and were somewhat more distressed than the non-users. The use of support organizations and complementary therapies appears to represent a thoughtful approach to dealing with the distress of cancer. The opinion of the oncologist regarding resource use was valued by nearly half of the sample.
Assuntos
Adaptação Psicológica , Neoplasias da Mama/psicologia , Recursos em Saúde/estatística & dados numéricos , Aceitação pelo Paciente de Cuidados de Saúde , Apoio Social , Adulto , Fatores Etários , Idoso , Neoplasias da Mama/terapia , Terapias Complementares , Análise Discriminante , Feminino , Humanos , Controle Interno-Externo , Pessoa de Meia-Idade , Quebeque , Ensaios Clínicos Controlados Aleatórios como Assunto , Grupos de Autoajuda , Inquéritos e QuestionáriosRESUMO
The patient with a spinal cord injury presents significant challenges to the nurse seeking to promote an optimal state of physical wellness and maximum independence with self-care. This article describes the nature of spinal cord injuries and their long-term effects on the gastrointestinal system. The preoperative and postoperative needs that the WOC nurse must consider when designing a care plan for the patient with a spinal cord injury and a colostomy are discussed, as well as the indications and efficacy of elective colostomy surgery as a management alternative for the neuropathic bowel.
Assuntos
Colostomia/enfermagem , Constipação Intestinal/cirurgia , Procedimentos Cirúrgicos Eletivos/enfermagem , Incontinência Fecal/cirurgia , Traumatismos da Medula Espinal/complicações , Constipação Intestinal/etiologia , Incontinência Fecal/etiologia , Humanos , Planejamento de Assistência ao Paciente , Assistência Perioperatória/métodos , Resultado do TratamentoRESUMO
The emotional coping of 205 patients newly diagnosed with cancer was evaluated every 4 months during a 1-year period. Patients received a psychosocial intervention either immediately (early intervention, EI), or after a 4-month delay (later intervention, LI). No significant differences were found between the two groups, except at 8 months, when the LI group was significantly less depressed, anxious, and worried, and felt more in control than the EI group. The LI group continued to have less worry related to illness at 12 months. Patients with high ego strength had low levels of distress at baseline and may not have needed the intervention. The emotional coping of patients with breast cancer improved during the year regardless of the intervention timing. Patients with other diagnoses appeared to benefit most from the IL. It was concluded that patients with low ego strength and diagnoses other than breast cancer might be at higher risk for psychosocial complications and could benefit from the intervention.